Fig. 1
From: Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration
Enhanced neuronal CB2 expression due to hTAUP301S overexpression in a late stage tauopathy transgenic mouse model. Quantitative real-time PCR determination of mRNA levels of a Cnr2, b Cnr1, c Iba1, d Gfap. All genes were normalized by Tbp (TATA-box binding protein) mRNA levels, n = 4–5 samples ± SEM. Asterisks denote significant differences ****p < 0.0001, comparing the indicated groups with the wild type mice according to one-way ANOVA followed by Tukey post-test. e Neuronal localization of the CB2 receptor in the hippocampus (CA2) of 12 months old hTAUP301S transgenic mice. Immunofluorescence with anti-MAP2 (wild mice) or anti-TAU (transgenic mice) (red), anti-CB2 (green), and nuclear staining with DAPI (blue). Arrows point to hTAUP301S protein aggregates. f Quantification of CB2-TAU positive neurons in the CA2 hippocampal area. Number of TAU+ or CB2-TAU+ neurons (n = 4 animals/experimental group) g Co-localization of neuronal CB2 receptor with aggregated TAU in the hippocampus (CA2). Immunofluorescence with anti-PHF-TAU (red), anti-CB2 (green), and nuclear staining with DAPI (blue) in the transgenic mice. h Immunofluorescence with anti-IBA1 (red), anti-CB2 (green), and nuclear staining with DAPI (blue)